



Press release

Zagreb, Croatia 30th November 2016

Adrijana Vinter appointed new Managing Director of Fidelta

Fidelta, a collaborative drug discovery company, has appointed Dr Adrijana Vinter, current head of business development, as new managing director of the company.

Adrijana will commence her new role from January 1st 2017, succeeding Dr Phil Dudfield who is retiring.

Adrijana obtained her PhD in Chemistry at the University of Zagreb in the field of new macrolide antibiotics and started her career in PLIVA 14 years ago working initially as a scientist. She obtained an MBA at Cotrugli Business School, Croatia, before moving into Business Development with the creation of Fidelta. She has successfully engineered and overseen the development of the Fidelta revenue stream resulting in significant year on year growth.

Under the new leadership, Fidelta's operations will continue seamlessly through delivering high quality services to the clients.

About Fidelta

Fidelta, a wholly-owned subsidiary of Galapagos NV, is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development. Fidelta has developed a new macrocyclic drug discovery platform, FideltaMacro.TM

Fidelta's objective is to deliver efficacious, safe and differentiated pre-clinical candidates for its clients. For more information, visit www.fidelta.eu